financetom
Business
financetom
/
Business
/
BioMatrix Infusion Pharmacy Closes Acquisition of LUX Infusion, Expanding National Ambulatory Infusion Footprint
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BioMatrix Infusion Pharmacy Closes Acquisition of LUX Infusion, Expanding National Ambulatory Infusion Footprint
Oct 20, 2025 8:02 AM

PLANTATION, Fla., Oct. 20, 2025 /PRNewswire/ -- BioMatrix Infusion Pharmacy today announced the successful acquisition of LUX Infusion, Alaska's premier ambulatory infusion center business, effective October 17, 2025. LUX operates three state-of-the-art infusion centers across Alaska, delivering high-quality, patient-centered care and earning a strong reputation for clinical excellence and trusted provider and payer partnerships.

"Our decision to acquire LUX Infusion is rooted in a shared commitment to advancing access, quality, and innovation in ambulatory infusion care," said Ted Kramm, Chief Executive Officer, BioMatrix Infusion Pharmacy. "Together, we are better positioned to transform infusion care delivery and ensure that patients nationwide receive the highest standard of treatment."

"We founded LUX to deliver clinical excellence in a setting of comfort and convenience. Proving this model in Alaska, while lowering costs for complex treatments, exceeded our expectations," said Lisa Bruce, Co-Founder of LUX Infusion. "Partnering with BioMatrix strengthens our commitment and allows us to expand this model nationwide, raising the standard of outpatient infusion care with partners who share our vision and values."

Strategic Benefits of the Acquisition

Through the integration of LUX Infusion, BioMatrix strengthens its national platform in several key ways:

Expand Our Reach: Adds three premier infusion centers in Alaska, advancing BioMatrix's ability to serve patients in key growth markets and meet the rising demand for infusion services.

Enhance Clinical Capabilities: Integrates LUX's highly skilled care teams and proven operating model into BioMatrix's growing nationwide network.

Accelerate Growth & Innovation: Combines resources to scale new infusion sites more efficiently and deliver expanded therapy options.

Expand Home Infusion Nursing: Extends BioMatrix's home infusion nursing capabilities into the Pacific Northwest, providing greater flexibility and access for patients who prefer care in the home setting.

Deliver Greater Value: Improves access, outcomes, and experiences for patients while deepening partnerships with providers and payers.

LUX Infusion has recently received NICA accreditation and designation of AICE-Ambulatory Infusion Center of Excellence, which reflects their unwavering commitment to delivering safe, high-quality and value-based infusion care.

With this acquisition, BioMatrix continues to evolve into one of the nation's most comprehensive infusion pharmacy providers—extending its reach into the Pacific Northwest and reinforcing its commitment to delivering best-in-class care for complex and chronic conditions.

About BioMatrix Infusion Pharmacy

BioMatrix Infusion Pharmacy is a trusted, independent specialty infusion pharmacy with decades of experience. Our compassionate care team helps patients navigate the often-challenging healthcare environment. We work closely with our patients, as well as their family and their healthcare providers, throughout the patient's journey, staying focused on continuity of care and optimal clinical outcomes. Every day, in every interaction, we are dedicated to making a difference in people's lives. For more information about BioMatrix, visit www.biomatrixsprx.com.

About LUX Infusion

LUX Infusion is Alaska's leading independent ambulatory infusion provider, offering safe, convenient, and cost-effective care for patients with acute and chronic conditions. With three state-of-the-art locations and a patient-first approach, LUX delivers exceptional outcomes, seamless provider coordination, and a superior patient experience compared to hospital-based infusion centers. For more information about LUX, please visit www.luxinfusion.com.

Media Contact:

Tara Marchese

Senior Director of Marketing, BioMatrix Infusion Pharmacy

[email protected]

954-908-7636

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomatrix-infusion-pharmacy-closes-acquisition-of-lux-infusion-expanding-national-ambulatory-infusion-footprint-302588314.html

SOURCE BioMatrix Infusion Pharmacy

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MNC Capital Remains Committed to Acquisition of Vista Outdoor at $42 Per Share
MNC Capital Remains Committed to Acquisition of Vista Outdoor at $42 Per Share
Jul 10, 2024
09:49 AM EDT, 07/10/2024 (MT Newswires) -- MNC Capital said on Wednesday that it continues to be committed to its $42 per share all-cash offer for Vista Outdoor ( VSTO ) and will remain open for the Vista Board to accept. While it wouldn't lower the buyout price, MNC Capital said that it has no intention of further increasing its...
NetApp Expands Capabilities for GenAI, VMware Cloud Workloads
NetApp Expands Capabilities for GenAI, VMware Cloud Workloads
Jul 10, 2024
09:53 AM EDT, 07/10/2024 (MT Newswires) -- NetApp ( NTAP ) said Wednesday it is expanding capabilities for cloud workloads including GenAI and VMware with launch of new features. The new features include BlueXP workload factory, GenAI Toolkit, and the BlueXP disaster recovery service, NetApp ( NTAP ) added. The company said it has also released a joint reference architecture...
Intevac Names Cameron McAulay CFO
Intevac Names Cameron McAulay CFO
Jul 10, 2024
09:47 AM EDT, 07/10/2024 (MT Newswires) -- Intevac ( IVAC ) said Wednesday it has named Cameron McAulay its chief financial officer. McAulay succeeds Kevin Soulsby, who has been interim CFO since August 2023 and will return to his position as corporate controller. McAulay was previously the finance chief of Transphorm until it was acquired by Renesas Electronics, Intevac (...
Becton, Dickinson Says it Exceeded 2023 Emissions Reduction Targets
Becton, Dickinson Says it Exceeded 2023 Emissions Reduction Targets
Jul 10, 2024
09:52 AM EDT, 07/10/2024 (MT Newswires) -- Becton, Dickinson ( BDX ) said Wednesday that it reduced its 2023 scope 1 and 2 science-based greenhouse gas emissions by 18%, exceeding its target of 13%. The medical technology company said it also received approval for its near and long-term emissions reduction goals from the Science Based Target initiative, SBTi. BD plans...
Copyright 2023-2026 - www.financetom.com All Rights Reserved